Diet Pill Online

Xenical is the most clinically researched anti-obesity medication in history, with more than seven clinical trials involving over 7000 patients worldwide.

Vitamin A, D, E and K and beta-carotene levels stayed within the normal range in the majority of patients in up to two full years of treatment .

Does not affect the brain Does not affect the heart or other parts of the body Side effects are controlled by diet.

We look forward to helping you gain the benefits of this proven and popular aid to effective weight loss.

Xenical is indicated for long-term treatment of significantly obese patients, including patients with risk factors associated with obesity, in conjunction with a mildly hypocaloric diet. Xenical is effective in long-term weight control (weight loss, weight maintenance and prevention of weight regain). Treatment with Xenical results in an improvement of risk factors and co-morbidities associated with obesity, including hypercholesterolemia, noninsulin dependent diabetes mellitus (NIDDM), impaired glucose tolerance, hyperinsulinemia, hypertension and in a reduction of visceral fat.

Experience from Clinical Trials :

The weight loss drug category may soon accept another member - Qnexa. The experimental drug showed impressive results in they're latest trials, as they're accredited with helping obese person lose up to 15% of their body weight without getting severe side effects often seen with other weight loss drugs.

Qnexa is a combination of two drugs that have already been approved for market: phentermine (Adipex), which is a commonly prescribed drug for weight loss and topiramate (Topamax), which is used to treat migraine and epilepsy. It has been formulated to be taken once daily.

Acomplia has been developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as 'the munchies'.

Acomplia works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite.

Filed for approval with the FDA in April 2005, it has encountered significant delays over the past two years. In February 2007, the company learnt that the FDA had extended their decision on whether or not to approve Acomplia by a further 3 months. Despite the repeated setbacks, analysts remain optimistic that it will eventually be approved in the US as an aid to weight loss.